Medium-Chain Triglycerides: Scientific and Regulatory Perspectives from Germany and Japan with a US Context-A Concise Review.
Level 5 - mechanism / opinion, no new human data
Narrative review of metabolism, clinical applications, and regulatory frameworks.
PubMed 41978079 · doi:10.3390/nu18071027
What was done
This concise narrative review summarized medium-chain triglyceride (MCT, C6–C12 fatty acids) metabolism, industrial synthesis (esterification of C8 and C10 fatty acids), clinical indications, and comparative regulatory frameworks in Germany/the European Union, Japan, and the United States.
What was found
The abstract reports no numerical or quantitative clinical data. It describes that MCTs exhibit rapid absorption, direct portal transport, efficient mitochondrial β-oxidation to produce acetyl-CoA and ketones, and alternative ω-oxidation preventing lipid accumulation under high flux. In Germany/the EU, MCTs are mainly utilized in Foods for Special Medical Purposes (FSMPs) for fat malabsorption, refractory epilepsy, and long-chain fatty acid oxidation disorders. In Japan, they are incorporated into functional foods (FOSHU and FFC) for healthy and older adults. In the United States, MCTs hold GRAS status and are marketed as food ingredients, dietary supplements, and medical foods.
Why it matters
The paper clarifies how regional regulatory environments shape whether MCTs are restricted strictly to clinical nutrition or commercialized more broadly into preventive and functional food sectors.
Limits
This is a non-systematic narrative review lacking a described search strategy, quality appraisal, or original empirical data. Clinical efficacy, optimal dosages, and adverse effect rates across indications are not reported in the abstract.
Cited by
- supports Medium-chain triglycerides were first clinically evaluated in the 1950s and 1960s as a therapeutic dietary intervention to promote weight gain in malnourished children.